Treatment of Ebola Virus Infection with Antibodies from Reconvalescent Donors
Open Access
- 1 March 2015
- journal article
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 21 (3) , 521-523
Abstract
Clinical evidence suggests that antibodies from reconvalescent donors (persons who have recovered from infection) may be effective in the treatment of Ebola virus infection. Administration of this treatment to Ebola virus–infected patients while preventing the transmission of other pathogenic viruses may be best accomplished by use of virus-inactivated reconvalescent plasma.Keywords
This publication has 14 references indexed in Scilit:
- Ebola: a call for blood transfusion strategy in sub-Saharan AfricaThe Lancet, 2014
- Solvent/detergent plasma: pharmaceutical characteristics and clinical experienceJournal of Thrombosis and Thrombolysis, 2014
- Profile and Persistence of the Virus-Specific Neutralizing Humoral Immune Response in Human Survivors of Sudan Ebolavirus (Gulu)The Journal of Infectious Diseases, 2013
- Postexposure antibody prophylaxis protects nonhuman primates from filovirus diseaseProceedings of the National Academy of Sciences, 2012
- Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenzaTransfusion, 2011
- Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companiesTransfusion, 2009
- First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in GermanyTransfusion, 2009
- Transfusion‐associated transmission of West Nile virus, United States 2003 through 2005Transfusion, 2006
- Transfusion‐transmitted viral infections: building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesisTransfusion, 2006
- Human asymptomatic Ebola infection and strong inflammatory responseThe Lancet, 2000